Regeneron Pharmaceuticals Inc. and Society for Science today announced the top 40 finalists in this year’s Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high school seniors.
Energy and Commerce Committee Health Subcommittee Ranking Member Rep. Anna G. Eshoo (D-CA), Ranking Member Rep. Frank Pallone, Jr. (D-NJ), and Oversight and Investigations Subcommittee Ranking Member Rep. Kathy Castor (D-FL) wrote to FDA Commissioner Robert M. Califf to urge the agency to move forward with guidance to improve the diversity of populations represented in clinical trials.
Jill DeSimone, a global pharmaceutical executive, joined Swim Across America’s board of directors.Â
NCI has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network will support the Biden-Harris administration’s Cancer Moonshot by investigating how to identify cancers earlier.
Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients’ immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
A study led by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the University of Helsinki, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard, sheds light on how variations in immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.Â
The Wistar Institute’s associate professor Mohamed Abdel-Mohsen demonstrated, with his lab and collaborators, a connection between viral damage to the gut and premature biological aging.Â
Magentiq-Eye Ltd., an Israel-based technology company founded in 2014, announced today a study on the performance of Magentiq-Colo CADe version has been published in Lancet Digital Health.
FDA approved Tagrisso (osimertinib) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
